Pharmafile Logo
Pharmafocus logo
Advanced Search

invokana

Showing 9 posts of 9 posts found.

european_commission_web

Europe extends Invokana indication to cover diabetic kidney disease in type 2 diabetes patients

July 3, 2020
Medical Communications, Research and Development Europe, Mundipharma, invokana

European Commission has moved to expand the existing approved indication for Mundipharma’s Invokana (canagliflozin), making it the first sodium glucose co-transporter …

News
janssen_latest_logo_on_sign

Janssen’s Invokana combo smashes primary and secondary endpoints in chronic kidney disease

April 16, 2019
Manufacturing and Production, Research and Development Janssen, cardiovascular, chronic kidney disease, diabetes, invokana, pharma

Janssen has unveiled promising new Phase 3 for its sodium-glucose transport (SGLT) protein-2 inhibitor Invokana (canagliflozin), showing that the therapy …

News

J&J’s Invokana becomes first FDA-approved oral diabetes drug to reduce cardiovascular event risk

October 31, 2018
Research and Development, Sales and Marketing FDA, J&J, JJ, invokana, pharma

The FDA has given the go-ahead for Johnson & Johnson’s drug Invokana (canagliflozin) for use in the risk reduction of …

News
jj_sign_on_wall

J&J stops Invokana trial early after success in kidney disease and type 2 diabetes

July 17, 2018
Manufacturing and Production, Research and Development J&J, JJ, Janssen, Johnson & Johnson, invokana, kidney disease, pharma, renal, type 2 diabetesm diabetes

Johnson & Johnson and research arm Janssen have taken the decision to terminate a Phase 3 trial evaluating the efficacy …

News

FDA issues warnings on Janssen, AstraZeneca diabetes drugs

June 15, 2016
Research and Development, Sales and Marketing AstraZeneca, FDA, Janssen, farxiga, invokana

The US Food and Drug Administration has issued a warning of the risk of acute kidney injury for the type-2 …

News
Janssen Velcade

NICE recommends Velcade for MCL, and three diabetes drugs

December 23, 2015
Sales and Marketing Forxiga, NICE, Velcade, invokana, jardiance, mantel cell lymphoma, mcl

NICE has published final guidance recommending Velcade (bortezomib) as a treatment for previously untreated mantle cell lymphoma (MCL).  In the …

News
fda_building

FDA strengthens safety warning for J&J’s diabetes drug Invokana

September 14, 2015
Sales and Marketing FDA, Food and Drugs Administration, Invokamet, J&J, JJ, Johnson & Johnson, diabetes, invokana, safety warning, type 2 diabetes

Johnson & Johnson has suffered a blow after the FDA strengthened its safety warning for the company’s type 2 diabetes …

News
Janssen image

NICE recommends tenth diabetes drug

June 26, 2014
Sales and Marketing Janssen, NHS, diabetes, invokana, type 2

In final guidance NICE has recommended Janssen’s Invokana as a treatment to help lower blood sugar levels in people with …

News
janssen image

Janssen’s diabetes drug Invokana recommended

January 11, 2013
Sales and Marketing Janssen, SGLT2, canagliflozin, diabetes, invokana

An FDA advisory committee has recommended Janssen’s new diabetes treatment canagliflozin for approval. To be marketed under the name Invokana, …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024